About
About Angalbio
Angalbio is a biotechnology company with operations in Qingdao and Suzhou. In 2022 it announced Greater China development and commercialization rights for a TGFBR2-targeting antisense candidate.
NVP-13 within Angalbio’s research focus
Our current leading scientific thesis concerns pathological TGF-β signaling in neurodegenerative and fibrotic diseases. NVP-13 is the flagship therapeutic program within that focus.
Our approach connects target biology, molecular interventions and translational evaluation. Antisense oligonucleotides are among the technologies used to pursue these questions.
Collaboration enquiries
We welcome discussions with researchers and clinical collaborators who share an interest in disease mechanisms and translational evidence. The appropriate contact route for pharmaceutical, licensing, development and investment enquiries still needs company confirmation.
Contact AngalbioCareers at Angalbio